Bichet DG - Search Results

1

Pharmacological chaperone action on G-protein-coupled receptors.

Bernier V, Bichet DG, Bouvier M. Bernier V, et al. Among authors: bichet dg. Curr Opin Pharmacol. 2004 Oct;4(5):528-33. doi: 10.1016/j.coph.2004.08.001. Curr Opin Pharmacol. 2004. PMID: 15351360 Review.

2

Functional rescue of the constitutively internalized V2 vasopressin receptor mutant R137H by the pharmacological chaperone action of SR49059.

Bernier V, Lagacé M, Lonergan M, Arthus MF, Bichet DG, Bouvier M. Bernier V, et al. Among authors: bichet dg. Mol Endocrinol. 2004 Aug;18(8):2074-84. doi: 10.1210/me.2004-0080. Epub 2004 May 27. Mol Endocrinol. 2004. PMID: 15166253

3

Pharmacological chaperones: potential treatment for conformational diseases.

Bernier V, Lagacé M, Bichet DG, Bouvier M. Bernier V, et al. Among authors: bichet dg. Trends Endocrinol Metab. 2004 Jul;15(5):222-8. doi: 10.1016/j.tem.2004.05.003. Trends Endocrinol Metab. 2004. PMID: 15223052 Review.

4

Pharmacologic chaperones as a potential treatment for X-linked nephrogenic diabetes insipidus.

Bernier V, Morello JP, Zarruk A, Debrand N, Salahpour A, Lonergan M, Arthus MF, Laperrière A, Brouard R, Bouvier M, Bichet DG. Bernier V, et al. Among authors: bichet dg. J Am Soc Nephrol. 2006 Jan;17(1):232-43. doi: 10.1681/ASN.2005080854. Epub 2005 Nov 30. J Am Soc Nephrol. 2006. PMID: 16319185

5

Pharmacological chaperones rescue cell-surface expression and function of misfolded V2 vasopressin receptor mutants.

Morello JP, Salahpour A, Laperrière A, Bernier V, Arthus MF, Lonergan M, Petäjä-Repo U, Angers S, Morin D, Bichet DG, Bouvier M. Morello JP, et al. Among authors: bichet dg. J Clin Invest. 2000 Apr;105(7):887-95. doi: 10.1172/JCI8688. J Clin Invest. 2000. PMID: 10749568 Free PMC article.

6

Pharmacological chaperones: a new twist on receptor folding.

Morello JP, Petäjä-Repo UE, Bichet DG, Bouvier M. Morello JP, et al. Among authors: bichet dg. Trends Pharmacol Sci. 2000 Dec;21(12):466-9. doi: 10.1016/s0165-6147(00)01575-3. Trends Pharmacol Sci. 2000. PMID: 11121835 Review.

7

Association of calnexin with wild type and mutant AVPR2 that causes nephrogenic diabetes insipidus.

Morello JP, Salahpour A, Petäjä-Repo UE, Laperrière A, Lonergan M, Arthus MF, Nabi IR, Bichet DG, Bouvier M. Morello JP, et al. Among authors: bichet dg. Biochemistry. 2001 Jun 12;40(23):6766-75. doi: 10.1021/bi002699r. Biochemistry. 2001. PMID: 11389590

8

Identification and characterization of an activating F229V substitution in the V2 vasopressin receptor in an infant with NSIAD.

Carpentier E, Greenbaum LA, Rochdi D, Abrol R, Goddard WA 3rd, Bichet DG, Bouvier M. Carpentier E, et al. Among authors: bichet dg. J Am Soc Nephrol. 2012 Oct;23(10):1635-40. doi: 10.1681/ASN.2012010077. Epub 2012 Sep 6. J Am Soc Nephrol. 2012. PMID: 22956819 Free PMC article.

9

A peptide derived from a beta2-adrenergic receptor transmembrane domain inhibits both receptor dimerization and activation.

Hebert TE, Moffett S, Morello JP, Loisel TP, Bichet DG, Barret C, Bouvier M. Hebert TE, et al. Among authors: bichet dg. J Biol Chem. 1996 Jul 5;271(27):16384-92. doi: 10.1074/jbc.271.27.16384. J Biol Chem. 1996. PMID: 8663163 Free article.

10

Vasopressin type 2 receptor V88M mutation: molecular basis of partial and complete nephrogenic diabetes insipidus.

Bockenhauer D, Carpentier E, Rochdi D, van't Hoff W, Breton B, Bernier V, Bouvier M, Bichet DG. Bockenhauer D, et al. Among authors: bichet dg. Nephron Physiol. 2010;114(1):p1-10. doi: 10.1159/000245059. Epub 2009 Oct 8. Nephron Physiol. 2010. PMID: 19816050

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

253 results

Search Page

Filters